News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
stocktitan.net Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 1,600,072 Units in Axiom Intelligence Acquisition Corp 1 (AXIN), representing 7.77% of the outstanding class. The filing specifies that all voting and dispositive power over these securities is shared, with no …
Axiom Intelligence Acquisition Corp 1 (AXIN) has reported total assets of $208.3 million as of June 30, 2026, and a net income of $2.27 million for the six months ended June 30, 2026, primarily from interest on trust investments. The SPAC has entered into …
Evaxion Biotech A/S (EVAX) has an earnings forecast score of 8.00, ranking 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $11.00 for EVAX, with a high of $16.00 and a low of $10.00. Most analysts recommend …
This article provides a technical analysis of Evaxion Biotech A/S (EVAX), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. The stock is currently trading between a resistance level of $3.35 and a support …
Evaxion Biotech A/S (EVAX) currently holds a financial score of 7.14, placing it 148th out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The report details various financial health dimensions including Quality of Earnings, Operational …
This article provides a revenue breakdown for Axiom Intelligence Acquisition Corp 1 (NASDAQ: AXINR) as listed on TradingView. It appears to be a financial data page rather than a traditional article, indicating that there are no current trade data, and it outlines various sections …
This article provides an analysis of Evaxion Biotech A/S (EVAX), focusing on its revenue breakdown. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article presents a current stock price and …
This article provides historical dividend and stock split information for Evaxion Biotech A/S (EVAX). It notes that no dividends have been distributed in the past five years. The article details several stock split events, predominantly mergers with ratios such as 5→1 and 10→1, occurring …
This article details the shareholder structure of Evaxion Biotech A/S (EVAX), listing major shareholders and their proportions, including institutional holdings over recent quarters. Key individual shareholders like Merck & Co Inc and Merck Sharp & Dohme Corporation are highlighted alongside a breakdown by shareholder …
This article provides a detailed cash flow statement for Evaxion Biotech A/S (EVAX), presenting quarterly data for operating, investing, and financing activities. It also includes explanations for each cash flow category and answers frequently asked questions regarding the company's financial performance, such as its …
This article provides a detailed risk assessment for Evaxion Biotech A/S (EVAX), focusing on its volatility, financial risk, and investment risk. It presents various statistical metrics including Beta, Value at Risk (VaR), Maximum Drawdown, Volatility, Return, Sharpe Ratio, Skewness, Standardised True Range, Downside Risk-Adjusted …
This article provides an overview of Axiom Intelligence Acquisition Corp (AXIN) focusing on its insider trading activity, institutional holdings, and other financial data. It highlights that there is no recent insider trading or Congress trading data available for AXIN, and details various metrics and …
This article provides a detailed profile of Axiom Intelligence Acquisition 1 Ord Shs Class A (AXIN), including its current market price of $10.270, market capitalization of $280.03 million, and P/E ratio of 31.20. It lists the company's executive management team, such as Richard H. …
This article provides a detailed quarterly and annual income statement for Evaxion Biotech A/S (EVAX). It includes key financial metrics such as total revenue, operating expenses, operating profit, net income, and basic/diluted earnings per share spanning several fiscal years and quarters. The data allows …
This article provides a detailed financial overview and analysis of Evaxion Biotech A/S (EVAX). It highlights the company's strong fundamentals, high growth potential, and current valuation, which is considered fairly valued within the Biotechnology & Medical Research industry. Analysts have rated EVAX as a …
Evaxion Biotech A/S (EVAX) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.88%, a 48.82% increase quarter-over-quarter. James Simons is the largest institutional shareholder with 0.47% …
This article provides a valuation analysis for Evaxion Biotech A/S (EVAX) as of July 24, 2026. The company currently holds a valuation score of 9.76, placing it 16th in its industry. Key financial metrics like P/E, P/B, P/S, and P/CF ratios are presented, with …
Terra Quantum, a quantum technology company, plans to go public on Nasdaq through a business combination with Axiom Intelligence Acquisition Corp 1 (NASDAQ: AXIN), a SPAC, in a deal valuing Terra Quantum at approximately $3.5 billion. The transaction is expected to close in the …
Evaxion Biotech (EVAX) released its Q4 2025 earnings report, showing an actual EPS of -$0.02, beating the consensus estimate of -$0.24. Revenue for the quarter was $0.00, meeting expectations. The next earnings report is estimated for August 20, 2026.
Search by ticker symbol or company name and select a result to open its chart.